Felty's syndrome is a rare disorder characterized as a systemic manifestation of severe rheumatoid arthritis associated with granulocytopenia and splenomegaly. We report a retrospective analysis of a series of seven patients treated successfully with low-dose methotrexate, leading to sustained clinical improvement (number of swollen joints) and normalization of the granulocyte count for an observation period of 1 yr. Our cohort is the largest ever published with methotrexate treatment of this rare condition. Our results confirm earlier single case reports suggesting methotrexate to be the first-choice treatment nowadays in Felty's syndrome.
P with severe, long-lasting and seropositive ( ESR), whole blood count and rheumatoid factor titration. Laboratory data were gathered regularly in rheumatoid arthritis (RA), leucopenia, especially granulocytopenia, and splenomegaly present the charour department during the first 4 weeks after the initiation of methotrexate therapy. The patients were acteristic features of Felty's syndrome, first described in 1924 by A. R. Felty [1]. Felty's syndrome is now then followed at regular intervals in our out-patient clinic. Concomitant medication, total joint count and considered a very rare systemic complication of RA, occurring in <1% of all RA patients [2] . Because of laboratory tests were available for all patients after an interval of 1 yr. this rarity, controlled studies of different treatment modalities are not available. Encouraged by the experiStatistical analysis was performed using Wilcoxon's signed rank test due to the small number of patients. ence of an unexpected good response of many patients with 'refractory RA' to methotrexate [3], we started Student's t-test was applicable only for the granulocyte count and the swollen joint count, as these data showed to introduce this compound in patients with Felty's syndrome as early as 1980. In the following years, all a normal distribution confirmed by x2 test. The ESR was not normally distributed. patients presenting with active disease in Felty's syndrome who attended our clinic were routinely treated RESULTS with low-dose methotrexate. In 1992, we analysed the clinical and laboratory data of these patients retro-
We identified seven patients with an established diagnosis of Felty's syndrome who were regarded as spectively to verify our impression that methotrexate was safe, effective and well tolerated in these patients.
having refractory RA followed for at least 1 yr after initiation of methotrexate therapy. Three patients had PATIENTS AND METHODS >2.0 × 109 granulocytes at the time, when methotrexate therapy was started, but these patients had docuPatients labelled as having a diagnosis of Felty's syndrome were identified using a computerized data mented granulocytopenia earlier in the course of their disease, thus fulfilling the diagnostic criteria. bank containing the diagnoses of all patients who were admitted to our hospital between 1978 and 1991. Then Table I shows baseline demographic and clinical characteristics of the seven patients. All patients were we reviewed the records of these patients, and confirmed the diagnosis, if the patients fulfilled the followfemale, their mean age was 60.6 yr (range 46-76). The mean disease duration of RA before entering the study ing criteria: RA according to ACR criteria [4], splenomegaly confirmed by ultrasound and granulowas 10.3 yr (range 4-18). All but one patient had positive rheumatoid factor testing, the seronegative cytopenia of <2.0 × 109/l recorded at any time during the disease course. Splenomegaly and neutropenia had patient also showed erosive disease. Table II shows the clinical data of the patients at to be unrelated to any other underlying disease or condition, or to the concomitant therapy. At admission baseline (t0) and 4 weeks (t1) and 1 year (t2) after the to the hospital, all patients underwent a detailed clinical initiation of methotrexate therapy. Between t0 and t1, until the effect is noticeable and~6-12 weeks until the maximum effect is reached [33, 34] , the dose and there was a statistically not significant increase in the mean granulocyte count from 1.95 to 2.39 × 109/l; the duration of the treatment in this patient may have been insufficient. after 1 yr, the mean granulocyte count was 3.92 × 109/l. This change was significant compared to
In our study, only one patient showed a slight decrease in the granulocyte count after 1 month of baseline as well as compared to t1. There was also a decrease in the mean ESR from 40.9 mm/h to therapy (patient 6), but the granulocyte count of 2.76 × 109/l was still within the normal limits and 29.8 mm/h after 1 month and to 26.6 mm/h after 1 yr, but this change did not reach statistical significance.
increased during the 1 yr follow-up. In all other patients, the granulocytes increased constantly during The mean joint count decreased significantly from 19.0 at baseline to 7.4 after 1 yr. Changes were significant treatment. This should therefore be interpreted as a treatment effect. using Wilcoxon's signed rank test at the level of P < 0.01. Student's t-test found identical results at Some of our patients started methotrexate with a granulocyte count of >2.0 × 109/l. These patients had almost the same level (P < 0.01 for the granulocyte count and P < 0.05 for the swollen joint count).
documented granulocytopenia earlier in the course of their disease unrelated to any other condition, DISCUSSION thus confirming the diagnosis of Felty's syndrome. Spontaneous variations in the granulocyte count occurOpen studies or case reports with different treatment methods have been published on Felty's syndrome, ring in a considerable number of patients in long-term observation have been described before [35] . usually with small sample sizes, showing a divergent response to splenectomy or splenic embolization [5],
The indication for starting methotrexate in our patients did not depend primarily on the haematolog--penicillamine [6 ], parenteral gold [7, 8] , cyclosporin [9] and high-dose i.v. gamma globulin [10] . ical findings, but was based on a still active rheumatic disease, as documented by the number of swollen joints Granulocyte stimulating factor (GSF ) was reported to lead to a normalization of granulocytopenia [11] [12] [13] [14] [15] , before treatment. The effect of methotrexate treatment on the clinical status of RA in Felty's syndrome in the but this treatment is often complicated by a flare of the disease [16, 17] . So the treatment of first choice is published cases has only been described in general terms, with the exception of three cases. We therefore still controversial.
Methotrexate therapy has been shown to be effective evaluated the count of swollen joints of all patients and found a significant decrease in the mean number and well tolerated both in controlled short-term [18] [19] [20] and in open long-term observational studies of swollen joints from 19.0 to 7.4 after 1 yr of treatment. There was a complete remission according to [21, 22] in RA. Several case reports have also been published using methotrexate in Felty's syndrome the clinical status (no swollen joints and ESR within normal values) in three patients (patients 4, 5 and 6), [23] [24] [25] [26] [27] [28] [29] [30] [31] . Table III lists all published cases that we could a substantial improvement in two patients (patients 3 and 7) and an almost unchanged status in two patients identify in the literature.
With the exception of one case [29] , they all reported (patients 1 and 2). Of the laboratory signs of inflammation, only the a favourable response. This was achieved even with small doses of methotrexate usually not exceeding ESR was available for all patients at all time points; the CRP was not regularly recorded. There was a 7.5 mg/week. The one patient reported not to improve on methotrexate by Guillemin and Pourel [29] was substantial decrease in ESR in four patients (patients 1, 2, 4 and 7), a small increase in two patients (patients treated with a 7.5 mg weekly oral dose for a period of only 1 month. As the efficacy of methotrexate is dose 3 and 6) and almost no change in one patient (patient 5). The mean ESR decreased from 50.9 to 26.6, but dependent, and as it usually takes at least 4 weeks this did not reach statistical significance due to the using higher doses of methotrexate in the long-term treatment. small numbers and the not normal distribution of the data.
The cause of the neutropenia in Felty's syndrome is still not sufficiently explained. Several hypotheses have The improvement of clinical and laboratory signs of Felty's syndrome in our patients was not due to the been proposed and numerous factors influencing granulocyte production or survival in peripheral blood have concomitant therapy, especially not to corticosteroids. Before treatment, only two patients were on low-dose been identified in patients with Felty's syndrome [24, 36, 37] . Which of these factors plays the most importcorticosteroids of no more than 5 mg prednisone/day. During the 1 yr of observation, one patient could stop ant role is still unclear. Our data cannot contribute to a further clarification of this problem, but as methotaking corticosteroids and in one patient prednisone was introduced at a dosage of 5 mg/day. The daily trexate is capable of various immunosuppressive actions [38] our findings again stress the important dose of prednisone could be reduced from a mean of 1.75 to 0.96 mg after 1 yr of treatment.
role of immunological factors in the development of neutropenia in Felty's syndrome. Compared with the other published cases, the methotrexate dose in our patients was higher (mean dose
In conclusion, our data confirm earlier reports that low-dose methotrexate therapy is a safe and effective 12.86 mg). This may also explain the good response of our patients. Besides this, the therapy was very well treatment of Felty's syndrome and that patients with unexplained neutropenia in RA should not be excluded tolerated and no major side-effects leading to discontinuation of the therapy occurred. from methotrexate treatment. The time of onset of the effect of methotrexate is usually expected at 4-6 weeks after initiation of therapy R [33] . Consistent with these expectations, an increase in
